Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: An experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy

Oncology Reports

Volumn 22, Issue 1, 2009, Pages 105-113

  Casneuf, Veerle F ^a   Demetter, Pieter ^b   Boterberg, Tom ^a   Delrue, Louke ^a   Peeters, Marc ^a   Van Damme, Nancy ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Gemcitabine; Pancreatic cancer; Radiotherapy; Sunitinib

Indexed keywords

CASPASE 3; CD31 ANTIGEN; EPIDERMAL GROWTH FACTOR; FAS ANTIGEN; GEMCITABINE; PLACEBO; PLACENTAL GROWTH FACTOR; SUNITINIB; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL PARAMETERS; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL STUDY; IMMUNOHISTOCHEMISTRY; MALE; MICROVESSEL DENSITY; MONOTHERAPY; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TREATMENT RESPONSE; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD95; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; EPIDERMAL GROWTH FACTOR; INDOLES; MALE; MICE; MICROVESSELS; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PREGNANCY PROTEINS; PROTEIN KINASE INHIBITORS; PYRROLES; RADIOTHERAPY, ADJUVANT; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 68249152630     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000412     Document Type: Article

References (53)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
2. Nitecki SS, Sarr MG, Colby TV and van Heerden JA: Long-term survival after resection for ductal adenocarcinoma of the pancreas: is it really improving? Ann Surg 221: 59-66, 1995.
3. Piorkowski RJ, Blievernicht SW, Lawrence W Jr, Madariaga J, Horsley JS III, Neifeld JP and Terz JJ: Pancreatic and periampullary carcinoma. Experience with 200 patients over a 12-year period. Am J Surg 143: 189-193, 1982.
4. Gudjonsson B: Cancer of the pancreas: 50 years of surgery. Cancer 60: 2284-2303, 1987.
5. Tepper J, Nardi G and Sutt H: Carcinoma of the pancreas: review of MGH experience from 1963-1973-analysis of surgical failure and its implications for radiation therapy. Cancer 37: 1519-1524, 1976.
6. Griffin JF, Smalley SR, Jewell W, Paradelo JC, Reymond RD, Hassanein RE and Evans RG: Patterns of failure after curative resection of pancreatic carcinoma. Cancer 66: 56-61, 1990.
7. Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet 363: 1049-1057, 2004.
8. Oettle H and Neuhaus P: Adjuvant therapy in pancreatic cancer. Drugs 67: 2293-2310, 2007.
9. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Child DS, Holbrook MA, Lavin PT, Livstone E, Spiro H, Knowlton A, Kasler M, Barkin J, Lessner H, Mann-Kaplan R, Ramming K, Douglas HO Jr, Thomas P, Nave H, Bateman J, Lokich J, Brooks J, Chaffey J, Corson JM, Zamcheck N and Novak JW: Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer 48: 1705-1710, 1981.
10. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A and Wils J: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230: 776-782, 1999.
11. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ and Büchler MW: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350: 1200-1210, 2004.
12. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Kudrimoti MR, Fromm ML, Haddock MG, Schaefer P, Willett CG and Rich TA: Fluorouracil vs gemcitabine chemotherapy before after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 299: 1019-1026, 2008.
13. Oettlle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koechler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B and Riess H: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297: 267-277, 2007.
14. Yeo CJ, Cameron JL, Lillemoe KD, Sohn TA, Campbell KA, Sauter PK, Coleman J, Abrams RA and Hruban RH: Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity and mortality. Ann Surg 236: 355-366, 2002.
15. Li CP, Chao Y, Chi KH, Chan WK, Teng HC, Lee RC, Chang FY, Lee SD and Yen SH: Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 57: 98-104, 2003.
16. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
17. Ducreux M, Boige V, Goéré D, Deutsch E, Ezra P, Elias D and Malka D: Pancreatic cancer: From pathogenesis to cure. Best Pract Res Clin Gastroenterol 21: 997-1014, 2007.
18. Kindler HL, Niedzwiecki D, Hollis D, Oraefo E, Schrag H, Hurwitz H, McLeod HL, Mulcahy MF, Schilsky RL and Goldberg RM: A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303 [abstract]. J Clin Oncol 25 (Suppl): 4508, 2007.
19. Philip PA, Benedetti C, Fenoglio-Preiser C, Zalupski M, Lenz H, O'Reilly E, Wong R, Atkins J, Abruzzese J and Blanke C: Phase III study of gemcitabine (G) plus cetuximab (C) versus gemcitabine in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (PC): SWOG S025 study [abstract]. J Clin Oncol 25 (Suppl): LBA4509, 207.
20. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M and Parulekar W: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966, 2007.
21. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R and Harris AL: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57: 963-969, 1997.
22. Willett CG, Kozin SV, Duda DG, di Tomaso E, Kozak KR, Boucher Y and Jain RK: Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. Semin Oncol 33 (Suppl 10): S35-S40, 2006.
23. Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, Evans DB, Tamm EP, Ng C, Pisters PW, Charnsangavej C, Delclos ME, O'Reilly M, Lee JE and Wolff RA: Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 24: 1145-1151, 2006.
24. Krempien R, Munter MW, Timke C, Friess H, Hartung G, Herfarth KK, Abdollahi A, Buchler MW, Huber PE and Debus J: Cetuximab in combination with intensity modulated radiotherapy (IMRT) and gemcitabine for patients with locally advanced pancreatic cancer: a prospective phase II trial [PARC-Study ISRCTN56652283] [abstract]. J Clin Oncol 25 (Suppl): 4573, 2007.
25. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G and Cherrington JM: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9: 327-337, 2003.
26. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ and Rini BI: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16-24, 2006.
27. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM and Casali PG: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomised controlled trial. Lancet 368: 1329-1338, 2006.
28. Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G and Hallahan DE: SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 63: 4009-4016, 2003.
29. Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB, Cherrington JM and Pryer NK: Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with 'standard of care' therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2: 1011-1021, 2003.
30. Fujimoto K, Hosotani R, Wada M, Lee JU, Koshiba T, Miyamoto Y, Tsuji S, Nakajima S, Doi R and Imamura M: Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. Eur J Cancer 34: 1439-1447, 1998.
31. Yeh TS, Jan YY, Chiu CT, Ho YB, Chen TC, Lee KF, Chan KM, Hsu JC, Hwang TL and Chen MF: Characterisation of oestrogen receptor, progesterone receptor, trefoil factor 1, and epidermal growth factor and its receptor in pancreatic cystic neoplasms and pancreatic ductal adenocarcinoma. Gut 51: 712-716, 2002.
32. Korc M: Pancreatic cancer-associated stroma production. Am J Surg 194: S84-S86, 2007.
33. Chang YT, Chang MC, Wei SC, Tien YW, Hsu C, Liang PC, Tsao PN, Jan IS and Wong JM: Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer. Pancreas 37: 145-150, 2008.
34. Cuneo KC, Geng L, Fu A, Orton D, Hallahan DE and Chakravarthy AB: SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int J Radiat Oncol Biol Phys 71: 873-879, 2008.
35. Abrams TJ, Lee LB, Murray LJ, Pryer NK and Cherrington JM: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2: 471-478, 2003.
36. Osusky KL, Hallahan DE, Fu A, Ye F, Shyr Y and Geng L: The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 7: 225-233, 2004.
37. Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM and Mendel DB: Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther 5: 1280-1289, 2006.
38. Tzeng CW, Frolov A, Frolova N, Jhala NC, Howard JH, Vickers SM, Buchsbaum DJ, Heslin MJ and Arnoletti JP: EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients. J Surg Res 143: 20-26, 2007.
39. Park JS, Qiao L, Su ZZ, Hinman D, Willoughby K, McKinstry R, Yacoub A, Duigou GJ, Young CS, Grant S, Hagan MP, Ellis E, Fisher PB and Dent P: Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways. Oncogene 20: 3266-3280, 2001.
40. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I and George DJ: Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 26: 3743-3748, 2008.
41. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW and Weichselbaum RR: Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59: 3374-3378, 1999.
42. Feron O: Targeting the tumor vascular compartment to improve conventional cancer therapy. Trends Pharmacol Sci 25: 536-542, 2004.
43. Jain RK: Molecular regulation of vessel maturation. Nat Med 9: 685-693, 2003.
44. Moeller BJ, Richardson RA and Dewhirst MW: Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev 26: 241-248, 2007.
45. Geng L, Donnelly E, McMahon G, Lin PC, Sierra-Rivera E, Oshinka H and Hallahan DE: Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61: 2413-2419, 2001.
46. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S and Lyden D: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438: 820-827, 2005.
47. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D and Persico MG: Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7: 575-583, 2001.
48. Wei SC, Tsao PN, Yu SC, Shun CT, Tsai-Wu JJ, Wu CH, Su YN, Hsieh FJ and Wong JM: Placenta growth factor expression is correlated with survival of patients with colorectal cancer. Gut 54: 666-672, 2005.
49. Parr C, Watkins G, Boulton M, Cai J and Jiang WG: Placenta growth factor is over-expressed and has prognostic value in human breast cancer. Eur J Cancer 41: 2819-2827, 2005.
50. Taylor AP, Rodriguez M, Adams K, Goldenberg DM and Blumenthal RD: Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: potential relationship to post-therapy tumor angiogenesis and recurrence. Int J Cancer 105: 158-164, 2003.
51. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, Autiero M, Wyns S, Plaisance S, Moons L, van Rooijen N, Giacca M, Stassen JM, Dewerchin M, Collen D and Carmeliet P: Anti-P1GF Inhibits Growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131: 463-475, 2007.
52. Sini P, Wyder L, Schnell C, O'Reilly T, Littlewood A, Brandt R, Hynes NE and Wood J: The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade. Clin Cancer Res 11: 4521-4532, 2005.
53. Kim WY and Kaelin WG Jr: Molecular pathways in renal cell carcinoma - rationale for targeted treatment. Semin Oncol 33: 588-595, 2006.